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Abstract
Severe Trauma is a multisystem disorder with a high 
mortality in an often young population. It offers a big challenge 
to the intensivist, and any help that is available might prove 
decisive in saving the patient’s life.
This case report highlights the use of two novel technologies 
in critically ill trauma patients, namely the use of activated 
recombinant factor VII (Novoseven®) to correct coagulopathy, 
and the use of a central venous oxygen saturation monitor 
(PresepTM with VigileoTM) to optimise perfusion.
Introduction
A 16 year old male, JH, presented to a primary health 
care centre with severe abdominal pain and abrasions in the 
right upper quadrant, following a blunt abdominal injury. At 
the time he was fully conscious with a Glasgow Coma Scale of 
15. Haemodynamically, he was maintaining a systolic blood 
pressure of 160mmHg, but he was tachycardic and pale. Initial 
treatment was with 500ml of Gelafundin®, and intramuscular 
pethidine for pain relief. He was then transported urgently to St. 
Luke’s Hospital A&E department for further management.
A computed tomography (CT scan) of the brain, thorax and 
abdomen revealed a large liver haematoma with free fluid and 
a liver laceration involving the right liver lobe. There was no 
intracranial pathology, and only small pulmonary contusions 
in the right lower lung. 
The patient was taken to theatre within the hour. Laparotomy 
confirmed a huge laceration of the right hepatic lobe, with major 
haemorrhage. Due to the extensive damage, the liver was 
packed and the abdomen closed.  The patient was transferred 
to intensive care, intubated and ventilated, as the extent of the 
tear made a rapid recovery highly unlikely. Invasive monitoring 
included central venous pressure (CVP), continuous invasive 
radial arterial blood pressure, peripheral oxygen saturation, and 
end-tidal carbon dioxide (MarquetteTM monitor). On admission, 
transfusion of blood and blood products was started to inhibit 
fibrinolysis.
In spite of transfusion of large doses of fresh frozen plasma, 
cryoprecipitate and platelets, it became apparent that the 
patient was becoming coagulopathic. Abdominal drains had to 
be emptied hourly (fresh blood).  Investigations showed a low 
platelet count and prolonged INR and APTT ratios confirming 
a coagulopathy. By now, a state of disseminated intravascular 
coagulopathy (DIC) was suspected, and tranexamic acid 
(Cyclokapron®) at a dose of 1g every 8 hours, and aprotinin 
infusion at a dose of 500,000 units per hour (Trasylol®) 
(following a loading dose) were started.
Eight hours post admission, JH remained haemodynamically 
unstable. A norepinephrine (noradrenaline) infusion was started 
to maintain a systolic blood pressure of around 100mmHg. A 
non-invasive, continuous cardiac output monitor (FlotracTM 
sensor connected to VigileoTM monitor, Edwards Lifesciences 
LLC, Irvine, CA) was set up. This demonstrated a hyperdynamic 
circulatory state, with cardiac output measurements reaching 
up to 20 l/min. At regular intervals this would drop suddenly 
to 8L/min (corresponding with a period of severe hypotension) 
indicating the need for further transfusion. 
As the situation was starting to look bleak a decision was 
taken to start activated recombinant Factor VII (rVFVIIa - 
Novoseven®, Novo Nordisk A/S, Bagsværd, Denmark). A dose 
of 90,000iu (1.8mg) every 8 hours was administered initially 
but this had to be reduced to 60,000iu (1.2mg) after 24 hours 
due to limited supplies. 
Twenty four hours post-admission, JH was still bleeding 
heavily and he was taken back to theatre.  The packs were 
replaced and no attempt was made to close the abdomen as the 
bowels were starting to swell and it was feared that the patient 
might develop an intra-abdominal compartment syndrome. 
After the second laparatomy JH was even more unstable.  His 
inotropic support now included epinephrine (adrenaline), his 
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oxygenation was severely impaired and bleeding continued 
unabated. 
At this point JH had received so much blood and blood 
products and lost so much blood through his open abdomen that 
assessing his intravascular volume status became difficult.  We 
felt the need to have a better indicator of tissue oxygenation.  A 
decision was taken to insert a  PresepTM catheter with VigileoTM 
monitor in order to assess the central venous oxygen saturation 
(ScvO2) as a surrogate of mixed venous oxygen saturation. 
The initial value of ScvO2 was 85% (indicating perfusion 
which was satisfying tissue oxygen demand). It was noticed that 
the drop in this value to less than 65% indicated a fresh episode 
of bleeding.  More importantly the drop happened well before 
the other parameters such as cardiac output and blood pressure 
changed.  Thus we could treat hypoperfusion before it started 
to harm his tissues.  At this time a large right haemothorax 
containing serosanguineous fluid was drained.
On the fourth day, JH stabilised.  It became possible to 
wean off inotrope infusions.  Transfusion requirements dropped 
dramatically and his tests of coagulation started to normalize. 
He was taken to theatre again for change of packs on the fifth 
day.  Bleeding had stopped so the packs were not replaced. 
His abdomen was closed on the 8th day and he was taken off 
ventilation on the 9th day. As expected after such a stormy 
week (Table 1) his postextubation course was complicated by 
a confusional state.  Generalized seizures made us scan his 
brain but this proved normal.  He remained febrile for several 
weeks but this too eventually settled.  He was transferred to a 
general surgical ward 27 days post admission and continued 
to recover.
Discussion
Activated Recombinant Factor VII
Factor VII (FVII), a vitamin K–dependent serine protease 
glycoprotein, is an important part of the coagulation pathway 
(Figure 1). Since the work by Alexander et al in 19511, it is 
Table 1: The daily progress of JH up to the seventh day
 Admission 1 2 3 4 5 6 7
 (night)
Lowest Hb 6.4 6.0 5.8 5.3 5.5 5.9 8.2 11.3
Highest INR 2.6 2.6 1.3  1.5 1.7 2.1 1.94 
Highest APPT 3.0 3.0 3.6  2.3 1.4 1.1 1.1 
Lowest Platelets 72 74 39 55 58 63 64 69
Packed Red Blood cells  (units)   5 15 14 2
Platelets (units) 6 12 44 6
Cryoprecipitate (units)  6 18 20 12 
Fresh Frozen Plasma (units)   7 20 18 8
average FiO2 .40 1.00 .60 .60 .40 .35 .35 .35
lowest pH 7.135 7.188 7.326 7.393 7.465 7.528 7.428 7.428
ScvO2   62-80% 82% 62-81% 79-87%  stopped
Hb: Haemoglobin (g/dL); INR: International Normalized Ratio; APPT: Activated Partial Prothrombin Time; Platelets (x109/L); FiO2: Fractional Inspired 
Oxygen concentration; ScvO2: central venous oxygen saturation
considered to be the key initiator of coagulation. It is found in 
plasma at a concentration of 0.5mg/L, with 1% of this being 
in the activated form (FVIIa). Both forms will bind to Tissue 
Factor (TF), and this binding facilitates conversion from FVII 
to FVIIa. The TF-FVIIa complex then enhances the conversion 
of factor IX to factors IXa and X to factor Xa, and hence initiates 
both the intrinsic and extrinsic pathways. For a summary of the 
properties of both FVII and FVIIa (Table 2).
Recombinant FVIIa (rFVIIa) – eptacog alpha (Novoseven®) 
- is produced by transfecting baby hamster cells with the F7 
gene.2,3 No human plasma-derived components are used in 
the formulation of rFVIIa, so there is no risk of human viral 
transmission.4 It is available as a dry powder for reconstitution, in 
vials with 1.2mg, 2.4mg, or  4.8mg of rFVIIa. After reconstitution 
each vial contains approximately 0.6mg/ml rFVIIa. Each ml 
would then contain 30,000units.4
The cost for this treatment (basic NHS Price) would be 
£664.72 for the 1.2mg preparation, £1,329.44 for the 2.4mg 
preparation, and £2,658.88 for the 4.8mg preparation.5
Figure 1: Coagulation cascade and the role of rFVIIa
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Mode of action
Its mode of action is similar to natural FVIIa, but it is not 
just a means of augmenting FVII levels. At the pharmacological 
doses given, rFVIIa attains concentrations up to 10 times higher 
than that found in blood. At these levels, rFVIIa does not need 
TF to initiate conversion of Factor X to Xa on activated platelet 
surfaces. This means that rFVIIa bypasses both the intrinsic 
and extrinsic pathways (Figure 1). Nevertheless its action is still 
localised to the area of endothelial damage where platelets are 
activated. It has a half-life of 2.7 hours, though this might be 
less in heavily bleeding patients.6
rFVIIa in trauma
rFVIIa is licensed by the US Food and Drug Administration 
for:
1. treatment of bleeding in individuals with haemophilia A 
and B with acquired inhibitors to FVII, FIX (licensed in 
1999).
2. persons with congenital factor VII deficiency (licensed in 
1999).
3. prevention of bleeding in surgical procedures for both 
inhibitor patients and FVII-deficient patients (licensed in 
2005).7
In the European Union, rFVIIa is also licensed for patients 
with Glanzmann’s thrombasthenia with antibodies to GPIIb 
IIIa and/or HLA, and showing poor response to platelet 
transfusions.4
Other unlicensed indications for rFVIIa include use in 
patients with liver disease, thrombocytopenia, or qualitative 
platelet dysfunction and in patients with no coagulation 
disorders who are bleeding as a result of extensive surgery or 
major trauma.
Most of the evidence to support the use of rFVIIa in trauma 
derives from case reports, with few clinical studies being 
performed. Use of rFVIIa for trauma patients started as early as 
1999, when Kenet et al8 published the first successful use of the 
drug in a soldier who had sustained a high velocity gunshot to the 
inferior vena cava, complicated with a traumatic coagulopathy. 
In liver trauma, Martinowitz et al9 showed that rFVIIa is effective 
in reducing blood loss in experimental Grade V liver trauma 
in swines with coagulopathy, but only if surgical control of 
the bleeding was obtained by packing. In another case series 
involving seven patients, Martinowitz and colleagues10 showed 
that the use of rFVIIa stopped the haemorrhage, decreased the 
number of blood products transfused, and improved laboratory 
markers of coagulopathy. The authors suggested that rFVIIa 
should be considered as an adjunctive haemostatic agent in 
trauma patients.
There are very few randomised controlled trials on the 
use of rFVIIa in trauma scenarios. One is that by Boffard and 
colleagues11, who reported the use of rFVIIa in 247 patients with 
penetrating or blunt injuries. The patients in the investigation 
arm were given an initial dose of 200μg/kg, then another two 
doses of 100μg/kg at one and three hours after admission. 
Controls received placebo injections. Statistically significant 
reductions in blood transfusions were observed for patients with 
blunt trauma, with trends in a reduction in mortality and critical 
complications, including ARDS. Similar trends were observed 
for patients with penetrating injuries. Sub-groub analysis12 
showed that coagulopathic trauma patients appear to derive 
particular benefit from early adjunctive rFVIIa therapy.
Dosage and safety
The recommended dose by the manufacturer for 
haemophiliacs is 30μg/kg in patients without inhibitors to 
Factor VII or VIII, and 90μg/kg in those with inhibitors. Since 
rFVIIa is not licensed for haemorrhagic situations except 
for haemophiliac patients, the exact dose to use in trauma is 
currently unknown. The dosages mentioned in the literature 
vary from low dose, such as 10μg/kg, to higher doses, up to 
212μg/kg.13
Once administered, bleeding usually stops in about 15 
minutes, but in a number of cases, repeated doses have had to 
be given. The dosage interval varies from 2 to 12 hours. 
Studies have been performed in order to demonstrate any 
factors which would help to select patients who would benefit 
from rFVIIa and those who would not. The major factor seems 
to be the pH, with acidosis causing a drastic loss of efficacy of 
the drug in vitro (up to 90% loss of efficacy at a pH of 7.10).14 
Clinical studies have confirmed this, together with adding the 
Revised Trauma Score and pre-administration PT as markers 
for futility for rFVIIa usage.15 It seems that early use of rFVIIa, 
before acidosis and haemorrhage become severe, might improve 
morbidity and mortality. This was confirmed in a study by 
Perkins and colleagues16, with patients receiving rFVIIa early 
requiring about 20% less blood products, but the reduction in 
complications and mortality was not statistically significant. 
Table 2: Summary of properties of FVII and FVIIa
 FVII FVIIa
Synthesis liver,  cleaved FVII
 coded by F7 (13q34)
Structure single chain, 48kDa two chains
  - light: 20kDa 
  - heavy 30kDa
Concentration 0.5mg/L  0.0036 mg/L
Half-time 3 – 6 hours  2.5 hours
  - increased with age, female gender, 
 pregnancy, Xa, thrombin, 
 hypertriglyceridemia IXa, XIa, XIIa
  - decreased with Warfarin, Vit K deficiency,
 liver failure, mutations
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Table 3: Side	effect	profile	of	rFVIIa
Adverse reactions
Most common: pyrexia, hemorrhage, injection site 
reaction, arthralgia, headache, hypertension, hypotension, 
nausea, vomiting, pain, edema and rash
Rare (0.1% - 0.01%): lack of effect
Very rare (<0.01%): Coagulopathic disorders such as 
increased D-dimers and consumptive coagulopathy; 
myocardial infarction; nausea; fever; pain (especially at 
injection site); increase in alanine transaminase, alkaline 
phosphatase, lactate dehydrogenase and prothrombin 
levels; cerebrovascular disorders including cerebral 




Arterial thrombotic events (such as myocardial 
infarction or ischaemia, cerebrovascular disorders and 
bowel infarction); venous thrombotic events (such as 
thrombophlebitis, deep vein thrombosis and pulmonary 
embolism). In the vast majority of cases, patients were 
predisposed to such events. 
Potential adverse reactions
Patients with disseminated intravascular coagulation 
(DIC), advanced atherosclerotic disease, crush injury, 
septicemia, or concomitant treatment with activated or 
nonactivated prothrombin complex concentrates (aPCCs/
PCCs) may have a potential risk of developing thrombotic 
events in association with NovoSeven treatment. 
Disseminated intravascular coagulation (DIC) was 
reported in a few patients who received NovoSeven during 
treatment with aPCCs/PCCs 
Anaphylaxis
No spontaneous reports of anaphylactic reactions, but 
patients with a history of allergic reaction should be 
carefully monitored. Contraindicated in patients with 
known hypersensitivity to NovoSeven or mouse, hamster, 
or bovine protein. 
One case of angioneurotic oedema reported in patient 
with Glanzmann’s thrombasthenia after administration of 
NovoSeven. 
Monitoring the use of rFVIIa is difficult. Firstly, rFVIIa is 
usually given to patients who are not responding to traditional 
management with fresh frozen plasma, cryoprecipitate and 
platelets. This means that any change in laboratory values 
would be difficult to attribute to rFVIIa alone. Most studies show 
that there is a decrease in prothrombin time and the activated 
thromboplastin time with the use of rFVIIa. Thromboelastogram 
studies demonstrate faster and better clot formation. There is 
no ideal way of assessing its effect:  how then do you decide 
whether to continue administration or whether to increase or 
decrease the dose? Furthermore, the use of concomitant platelet 
transfusion is debatable, but rFVIIa does need an adequate 
platelet count in order to work. 
There have been concerns regarding the effect of rFVIIa on 
thromboembolic rates. Although sporadic cases of deep venous 
thrombosis and pulmonary embolism, cerebrovascular events, 
and even right atrial thrombosis have been described in case 
reports, the complication rate is not high.17 For instance, during 
the period 1996–2000, more than 140,000 doses of rFVIIa were 
administered for haemophilia, with a complication rate of less 
than 0.02%.18 The complication rate may be higher if the doses 
used in trauma are administered.
rFVIIa is a recombinant protein, and hence one would 
expect common adverse reactions such as fever, injection 
site reaction, arthralgia, headache, nausea, vomiting, pain, 
oedema and rash. Patients who show allergies to mouse, 
hamster, or bovine protein should not be exposed to the 
drug (Table 3).
rFVIIa in our case
In our case, rFVIIa was started shortly after admission. 
JH was already in established DIC, and like most other 
patients described in the literature, he had been given 
conventional haemostatic agents, with little effect. We used 
a dose of 90,000 units (1.8mg) initially, then 60,000 units 
(1.2mg), which would correspond to a dose of 30μg/kg and 
20μg/kg respectively. This would probably be considered as 
a low-dose, although lower doses have been mentioned in 
the admittedly scanty trauma literature.
The use of rFVIIa in our patient did not result in an abrupt 
termination of bleeding. In fact, treatment had to be continued 
for two days, for 8 doses, before bleeding was controlled.  This 
could be due to a number of factors. The ongoing DIC in our 
patient would have resulted in a massive consumption of rFVIIa, 
with a loss of effect at the target site. Furthermore, the liver packs 
themselves used to control the bleeding might have propagated 
the DIC. Finally, the rFVIIa might have been inefficacious in this 
case due to inadequate dose. Our patient did have an acidosis 
before the second laparotomy, but this was controlled by the 
time rFVIIa was started. It might also be that the levels in the 
blood increased gradually with each dose until an adequate 
concentration allowed clotting to occur.
It must be noted that trauma management is a complicated 
issue, and the outcome, that is survival, is not solely dependent 
on the amount of bleeding. Organ failure and sepsis are 
complicating factors that have dramatic effects on mortality. 
Hence, the reduction in transfusions, and better control of 
bleeding with rFVIIa may not necessarily translate into better 
survival. As an example, in a study by Payne19, 68% of patients 
with bleeding, due to either haematological (30% of patients) or 
due to surgical causes (53%), who were given rFVIIa responded 
to the drug. However, only 40% survived, with the highest 
mortality being registered in the patients with bleeding of 
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haematological cause. This was confirmed in a recent study by 
Rizoli20, who showed that there was a strong reduction in early 
mortality (within 24 hours), but the trend for better overall 
mortality was not statistically significant. 
Although it is difficult to prove that the use of rFVIIa proved 
life-saving, we feel that the treatment was one determining factor 
in our patient’s survival. 
Central venous oygen saturation monitoring
The oxygen saturation of blood returning to the heart is 
a measure of the balance between oxygen supply and oxygen 
demand. In turn, this reflects cardiac output, haemoglobin 
levels, and arterial oxygen saturation (oxygen supply), and the 
tissue metabolism (oxygen demand), as shown in Figure 2.
Anything which upsets either the supply or the demand 
will result in a deviation from the normal values of 60 – 80%. 
The venous saturation will only truly reflect the global tissue 
perfusion if it is sampled in the pulmonary arteries (mixed 
venous oxygen or SvO2).  Accessing the pulmonary arteries 
requires the insertion of a pulmonary artery catheter.  The 
insertion of a pulmonary artery catheter carries a risk of 
complications which some people deem unjustifiable. A less 
risky alternative would be useful.  An alternative site is venous 
blood sampled from a central venous catheter i.e. a central 
venous oxygen saturation: ScvO2.  This will sample blood from 
the superior vena cava (head and upper body).
The evidence
Reinhart has shown that in anaesthetised dogs, the 
correlation coefficient between SvO2 and ScvO2 over a broad 
range of cardiorespiratory conditions, including hypoxia, 
haemorrhage, and resuscitation was 0.97.23 However, the values 
were not identical, and not interchangeable for the purpose of 
calculating shunt fractions. The study by Ladakis24  was one of a 
number of studies which showed that such a relationship existed 
even in critically ill patients, but others have proven otherwise.24 
However, all studies in the literature note that ScvO2 is always 
higher than SvO2, by about 5 – 18%.
23,25-27 Hence, it is necessary 
to use a higher threshold for action, with the literature quoting 
a figure of around 75% at which complications are avoided.28, 
29 Also, all studies have shown that the trend in ScvO2 follows 
that of SvO2.
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In the majority of cases a decrease in SvO2 and ScvO2 
represents an alert that the global oxygenation of tissues is 
inadequate, regardless of the source of this decrease. Examples 
are shown in Figure 2.
An increasing number of studies are showing that using 
the ScvO2 in a clinical protocol does improve the outcome in a 
critical care setting.28,29 Rivers and coworkers31 used continuous 
ScvO2 monitoring in an early goal-directed therapy algorithm in 
severe sepsis and septic shock patients. With a threshold ScvO2 
of 70%, the mortality rate in the treatment arm was decreased 
by 16.7% in comparison with the control group. This study forms 
the basis for the recommendation for early goal-directed therapy 
by the Surviving Sepsis Group (Figure 3).
Figure 2: Oxygen balance between oxygen delivery and 
oxygen demand
Table 4: Using the PresepTM Catheter with the VigileoTM 
monitor30
Prepare patient for central venous access
Calibrate system using in vitro method
• with PresepTM still unflushed and with calibration cup 
still on, connect optical module to monitor.
• enter haemoglobin level.
• calibrate.
• insert catheter into patient with aseptic technique.
• use ScvO2 as per ITU protocols.
Use PresepTM as normal central line
Every 12-24 hours, or prn, perform in vivo calibration
• setup monitor for in vivo calibration.
• press DRAW BLOOD on menu, then slowly draw 2ml 
of venous blood over 30 seconds, from distal port of 
PresepTM catheter. (This will allow monitor to time the 
sample.)
• send sample for co-oximetry, if necessary also for 
haemoglobin estimation.
• use values in order to continue the calibration process.
In haemorrhage, ScvO2 has been found to be a reliable 
marker of the extent of blood loss. Scalea et al32 have found 
that only ScvO2 and the cardiac index (in itself a strong 
determinant of ScvO2) showed a linear relationship to blood 
loss in anaesthetized dogs. Tissue extraction started to increase 
when blood loss was only 3-6% of circulating blood volume. 
In humans, a blood loss of 100ml would reduce SvO2 by about 
1%.33 Furthermore, even in patients who appear stable when 
monitored by heart rate, blood pressure, pulse pressure, urine 
output, central venous pressure, a ScvO2 of 65% is related to 
more serious injuries, and blood transfusions.34 Hence ScvO2 
may be considered to be an early marker of decompensation.
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Measuring ScvO2
ScvO2 can be measured in two ways: by analysing sampled 
blood with a co-oximeter (venous blood gas), or by continuous 
reflection spectrophotometry. Although the former is considered 
the gold standard, it is cumbersome, requires nursing staff to 
repeatedly sample blood and can only be done intermittently. 
Spectrophotometry is a relatively new technique that has been 
found to have good clinical correlation with co-oximetry.27 
Current central venous catheters with such saturation probes 
at the distal end, such as the PresepTM, need to be calibrated 
against a co-oximeter, both before insertion and during its 
use (Table 4), since the absorption spectrum of red blood cells 
depends on the relative concentrations of oxyhaemoglobin and 
haemoglobin. Hence, calibration should be performed more 
frequently in unstable patients, or in those with frequent changes 
of haemoglobin (company quotes changes of 6% or more35).
ScvO2 in practice
The use of ScvO2 is being promoted as a means of quickly 
identifying sudden deteriorations in the clinical condition of 
the patient before decompensation occurs. It is also being 
integrated in clinical protocols as an end-target parameter, 
the most notable of such protocols31 being incorporated in the 
Surviving Sepsis Campaign 2004 guidelines (Figure 3).36 In 
trauma, it has already been shown that a decrease in ScvO2 is 
one of the earliest signs of bleeding, since an increase in oxygen 
extraction is one of the earliest compensatory mechanisms, 
even before any changes in heart rate, systolic, mean and 
diastolic blood pressure, and stroke index.37 
The PresepTM was used late in the case of JH, on the third 
day after his admission. Hence its use in this case cannot 
be described as an “early goal-directed therapy.” Still, the 
PresepTM did allow us to pick up new episodes of bleeding, 
since each time this happened, the value dipped to 60%. In 
fact, not even the use of a non-invasive, pulse-contour cardiac 
output monitor proved to be adequate in the case of JH, since 
it did not give us early warning of bleeding. Pulmonary artery 
catheters with spectrophotometry are available locally, but the 
use of the pulmonary artery catheter in our ITU has become 
rare, so we felt that the use of the PresepTM offered a better 
risk-to-benefit ratio.
To obtain the best use of central venous saturation 
monitoring, it is important to realise that the catheter alone 
does not improve prognosis. Rather, it is the use of the 
information to direct therapy which alters outcome. Ideally 
it should be used in the context of previously established 
guidelines. We shall be introducing these guidelines in the 
near future.
Conclusion
The use of two new techniques allowed us to optimise the 
management of a critically ill victim of blunt abdominal trauma 
with massive liver injury and severe coagulopathic bleeding. 
We recommend the establishment of local guidelines to guide 
the use of these techniques. 
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